Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.43	$1.73	$1.43 ▼ $5.97	$19.98M	1.26	41,932 shs	59,066 shs
CPHI China Pharma	$1.83 +5.2%	$1.87	$1.20 ▼ $3.35	$5.96M	0.77	74,788 shs	36,466 shs
GRCE Grace Therapeutics	$2.97 +1.0%	$2.82	$1.75 ▼ $4.97	$41.08M	0.89	53,117 shs	21,118 shs
SCLX Scilex	$6.05 +14.2%	$4.99	$3.60 ▼ $78.05	$42.05M	1.13	67,948 shs	181,514 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	0.00%	-12.80%	-14.08%	-25.13%	-63.89%
CPHI China Pharma	0.00%	+4.40%	+14.13%	-93.08%	-92.65%
GRCE Grace Therapeutics	0.00%	-1.00%	+6.45%	+30.26%	+296,999,900.00%
SCLX Scilex	0.00%	+23.22%	+17.93%	-30.44%	-91.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	3.2001 of 5 stars	3.5	4.0	2.6	3.3	0.0
CPHI China Pharma	0.1131 of 5 stars	0.0	3.0	0.0	0.8	0.0
GRCE Grace Therapeutics	2.3686 of 5 stars	3.5	0.0	2.0	0.8	1.3
SCLX Scilex	2.2937 of 5 stars	3.3	2.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$18.00	1,158.74% Upside
CPHI China Pharma	0.00	N/A	N/A	N/A
GRCE Grace Therapeutics	3.00	Buy	$12.00	304.04% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	7,420.66% Upside

Current Analyst Ratings Breakdown

Latest CPHI, SCLX, CALC, and GRCE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/2/2025	GRCE Grace Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
4/11/2025	SCLX Scilex	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/11/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/2/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$770.00 ➝ $630.00
4/1/2025	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$1.07 per share	N/A
CPHI China Pharma	$4.30M	1.39	N/A	N/A	$0.70 per share	2.61
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$4.86 per share	N/A
SCLX Scilex	$56.59M	0.74	N/A	N/A	($27.68) per share	-0.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.56	N/A	N/A	N/A	N/A	-171.81%	-100.43%	8/11/2025 (Estimated)
CPHI China Pharma	-$3.08M	N/A	0.00	∞	N/A	-85.56%	-63.93%	-31.42%	N/A
GRCE Grace Therapeutics	-$9.57M	-$1.16	N/A	N/A	N/A	N/A	-19.45%	-16.99%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-146.93%	N/A	-82.65%	8/12/2025 (Estimated)

Latest CPHI, SCLX, CALC, and GRCE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/20/2025	Q4 2025	GRCE Grace Therapeutics	-$0.23	-$0.21	+$0.02	$0.01	N/A	N/A
5/14/2025	Q1 2025	CALC CalciMedica	-$0.43	-$0.36	+$0.07	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	0.79	5.66	5.66
CPHI China Pharma	0.22	0.79	0.26
GRCE Grace Therapeutics	N/A	11.77	11.77
SCLX Scilex	N/A	0.10	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
CPHI China Pharma	N/A
GRCE Grace Therapeutics	6.08%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
CPHI China Pharma	17.32%
GRCE Grace Therapeutics	13.51%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
CPHI China Pharma	250	3.26 million	15.92 million	Not Optionable
GRCE Grace Therapeutics	N/A	13.83 million	11.96 million	N/A
SCLX Scilex	80	6.95 million	6.40 million	Optionable

CPHI, SCLX, CALC, and GRCE Headlines

Recent News About These Companies

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25, 2025 | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

Scilex treatment of pericarditis granted FDA orphan designation

April 17, 2025 | markets.businessinsider.com

Scilex confirms FDA awards orphan drug designation for colchicine

April 17, 2025 | markets.businessinsider.com

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

April 16, 2025 | globenewswire.com

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

April 15, 2025 | globenewswire.com

Scilex announces 1-for-35 reverse stock split

April 12, 2025 | markets.businessinsider.com

D. Boral Capital Downgrades Scilex Holding (SCLX)

April 12, 2025 | msn.com

Scilex downgraded to Hold from Buy at D. Boral Capital

April 11, 2025 | msn.com

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

April 11, 2025 | globenewswire.com

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

March 26, 2025 | globenewswire.com

Scilex Holding Company Announces Change of Record Date for Preferred Stock Dividend

March 12, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPHI, SCLX, CALC, and GRCE Company Descriptions

CalciMedica NASDAQ:CALC

$1.43 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.52 +0.10 (+6.64%)

As of 06/27/2025 07:56 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

China Pharma NYSE:CPHI

$1.83 +0.09 (+5.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$1.81 -0.02 (-0.88%)

As of 06/27/2025 07:59 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Grace Therapeutics NASDAQ:GRCE

$2.97 +0.03 (+1.02%)

As of 06/27/2025 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Scilex NASDAQ:SCLX

$6.05 +0.75 (+14.15%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.06 +0.00 (+0.08%)

As of 06/27/2025 07:57 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time